


# Structure-Guided Engineering of a Pacific Blue Fluorophore Ligase for Specific Protein Imaging in Living Cells

Justin D. Cohen, Samuel Thompson, and Alice Y. Ting\*

Department of Chemistry, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States

Supporting Information



**ABSTRACT:** Mutation of a gatekeeper residue, tryptophan 37, in *E. coli* lipoic acid ligase (LplA), expands substrate specificity such that unnatural probes much larger than lipoic acid can be recognized. This approach, however, has not been successful for anionic substrates. An example is the blue fluorophore Pacific Blue, which is isosteric to 7-hydroxycoumarin and yet not recognized by the latter's ligase (W37VLplA) or any tryptophan 37 point mutant. Here we report the results of a structure-guided, two-residue screening matrix to discover an LplA double mutant, E20G/W37TLplA, that ligates Pacific Blue as efficiently as W37VLplA ligates 7-hydroxycoumarin. The utility of this Pacific Blue ligase for specific labeling of recombinant proteins inside living cells, on the cell surface, and inside acidic endosomes is demonstrated.

Probe incorporation mediated by enzymes (PRIME) is a method to tag recombinant proteins in living cells with chemical probes. The method utilizes mutants of *E. coli* lipoic acid ligase (LplA), whose natural function is to ligate lipoic acid onto acceptor proteins involved in oxidative metabolism. Instead of lipoic acid, LplA mutants catalyze the covalent attachment of unnatural chemical probes, such as 7-hydroxycoumarin, an aryl azide, on an alkyl azide, onto recombinant proteins fused to a 13-amino acid recognition sequence called LAP (LplA acceptor peptide). The advantages of PRIME in comparison to other protein labeling methods are the small tag size, compatibility with the interior of living cells, and high labeling specificity.


In previous studies, uptake of the unnatural substrate by LpIA was achieved by mutation of a "gatekeeper" residue, W37, at the end of the lipoic acid binding pocket (Figure 1B). Enlarging this pocket, for example by a W37  $\rightarrow$  V mutation, allows LpIA to accept structures much larger than lipoic acid, such as the blue fluorophore 7-hydroxycoumarin (HC)<sup>2</sup> (Figure 1A, top). In the course of our screening, however, we discovered several structures that are not accepted by W37 point mutants. One of the most interesting examples is Pacific Blue (PB),<sup>7</sup> a fluorophore that differs from HC only in the two fluorine atoms at C6 and C8 of the coumarin ring (Figure 1A, bottom). Because of these two electron-withdrawing fluorines, PB has a reduced 7-hydroxyl p $K_a$  of 3.7, compared to 7.5 for HC,<sup>7</sup> and is therefore fully anionic and fluorescent at physiological pH (7.4)

as well as endosomal pH (5.5-6.5). In contrast, only  $\sim 50\%$  of HC is in the anionic and fluorescent form at pH 7.4, and it is mostly protonated and hence nonfluorescent in acidic endosomes.

We hypothesized that PB is not recognized by HC's ligase, W37VLplA, and other W37 point mutants because its negative charge clashes with the mostly hydrophobic binding pocket of LplA. In addition, near the W37 gatekeeper residue at the end of the lipoic acid binding tunnel is a negatively charged side chain, E20, that may electrostatically repel PB (Figure 1B). E20 could play a steric role as well, since a previous alanine scan in the lipoate binding pocket identified E20A as one of two mutants (along with W37A) with any detectable ligation activity for an aryl azide probe.

The goal of this work was to use PB as a model compound to explore strategies for engineering new LplA activity, such as recognition of anionic substrates, beyond point mutations at W37. A PB ligase is also a useful alternative to HC ligase for studying proteins in acidic cellular compartments, where HC fluorescence is very low. By performing in-vitro screens using a panel of E20 and W37 single and double mutants, we discovered that E20G/W37TLplA ligates PB with comparable

Received: July 6, 2011
Revised: August 20, 2011
Published: August 23, 2011



**Figure 1.** Engineering a Pacific Blue (PB) ligase. (A) Fluorophore ligations catalyzed by mutants of lipoic acid ligase (LplA). The top row shows ligation of 7-hydroxycoumarin (HC) by W37VLplA onto a LAP (LplA acceptor peptide)<sup>5</sup> fusion protein, demonstrated in previous work.<sup>2</sup> The bottom row shows ligation of PB by E20G/W37TLplA, demonstrated in this work. (B) Cut-away view of wild-type LplA in complex with lipoyl-AMP ester, the intermediate of the natural ligation reaction. Adapted from PDB ID 3A7R.<sup>8</sup> W37 and E20 side chains are highlighted. (C) Modeled structure of E20G/W37TLplA in complex with PB-AMP ester. The PB-AMP conformation was energetically minimized using Avogadro.<sup>13</sup>

Model of E20G/W37TLpIA

+ Pacific Blue-AMP

kinetics to W37VLplA ligation of HC (Figure 1A). We demonstrated the utility of our PB ligase for in-vitro, cell surface, and intracellular site-specific protein labeling.

## **■ EXPERIMENTAL PROCEDURES**

Wild-type LpIA

+ Lipoyl-AMP

**Plasmids.** The LplA-pYFJ16 plasmid was used for bacterial expression of LplA.<sup>2</sup>

The LplA-pcDNA3 plasmid was used for mammalian expression of LplA. For mammalian expression of LAP fusion proteins, LAP-YFP-NLS-pcDNA3, LAP4.2-neurexin-1 $\beta$ -pNICE, and vimentin-LAP in Clontech vector were used and have been described. The LAP sequence used was GFEIDKVWYDLDA. For some constructs (neurexin and LDL receptor), an alternative peptide sequence called LAP4.2 was used instead (GFEIDKVWHDFPA). LAP4.2-LDLR-pcDNA4 was generated from HA-LDLR-pcDNA4<sup>10</sup> by a two-stage QuikChange to insert the LAP4.2 sequence and was a gift from Daniel Liu (MIT). The nuclear YFP transfection marker was H2B-YFP and has been described.

All mutants were prepared by QuikChange mutagenesis.

**LpIA Expression and Purification.** LpIA mutants were expressed in BL21 *E. coli* and purified by His<sub>6</sub>-nickel affinity chromatography as previously described.<sup>2</sup>

## In-Vitro Screening of LpIA Mutants (Figure 2A).

Ligation reactions were assembled as follows for Figure 2A: 2  $\mu$ M purified LplA mutant, 150  $\mu$ M synthetic LAP peptide (GFEIDKVWYDLDA; synthesized by the Tufts Peptide Synthesis Core Facility), 5 mM ATP, 500  $\mu$ M fluorophore probe, 5 mM magnesium acetate, and 25 mM Na<sub>2</sub>HPO<sub>4</sub> pH 7.2 in a total volume of 25  $\mu$ L. Reactions were incubated for 12 h at 30 °C.

LplA mutant/probe combinations giving high activity under these conditions were then reassayed with 10-fold lower probe (50  $\mu$ M) for 2 h.

Product formation was analyzed by ultraperformance liquid chromatography (UPLC) on a Waters Acquity instrument using a reverse-phase BEH C18 column 1.7  $\mu$ M (1.0 × 50 mm) with inline mass spectroscopy. Chromatograms were recorded at 210 nm. A gradient of 30–70% (acetonitrile + 0.05% trifluoroacetic acid) in (water with 0.1% trifluoroacetic acid) over 0.78 min was used.


Further in-Vitro Screening of Top Five LpIA Double Mutants (Figure 2B,C). Reactions for the top five LpIA double mutants were assembled as above, but with 500  $\mu$ M probe and a reaction time of 45 min. Reactions were quenched with EDTA to a final concentration of 100 mM. Product formation was analyzed on a Varian Prostar HPLC using a reverse-phase C18 Microsorb-MV 100 column (250  $\times$  4.6 mm). Chromatograms were recorded at 210 nm. We used a 10 min gradient of 30–60% acetonitrile in water with 0.1% trifluoroacetic acid under 1 mL/min flow rate. Percent conversions were calculated by dividing the product peak area by the sum of (product + starting material) peak areas.

**Michaelis**–**Menten Kinetic Assay.** The Michaelis–Menten curve shown in Figure S4 was generated as previously described. Reaction conditions were as follows: 2  $\mu$ M E<sup>20G/W37T</sup>LplA, 600  $\mu$ M synthetic LAP peptide, 2 mM magnesium acetate, and 25 mM Na<sub>2</sub>HPO<sub>4</sub> pH 7.2.

Mammalian Cell Culture and Imaging. HEK and HeLa cells were cultured in growth media consisting of Minimum Essential Medium (MEM, Cellgro) supplemented with 10% fetal bovine serum (FBS, PAA Laboratories). Cells were maintained at 37 °C under 5% CO<sub>2</sub>. For imaging, HEK cells were grown on glass coverslips pretreated with 50  $\mu$ g/mL fibronectin (Millipore) to increase their adherence.

Cells were imaged in Dulbecco's Phosphate Buffered Saline (DPBS) at room temperature. The images in Figures 3 and 4 were collected on a Zeiss AxioObserver.Z1 microscope with a 40× oil-immersion objective and 2.5× Optovar, equipped with a Yokogawa spinning disk confocal head containing a Quadband notch dichroic mirror (405/488/568/647 nm). Pacific Blue/coumarin (405 nm laser excitation, 445/40 emission filter), YFP (491 nm laser excitation, 528/38 emission filter), Alexa Fluor 568 (561 nm laser excitation, 617/73 emission filter), and DIC images were collected using Slidebook software (Intelligent Imaging Innovations). Images were acquired for 100 ms to 1 s using a Cascade II:512 camera. Fluorescence images in each experiment were normalized to the same intensity range.

**Cell Surface Labeling.** HEK cells were transfected with 200 ng of LAP4.2-LDLR-pcDNA4 and 100 ng of H2B-YFP cotransfection marker plasmid, per 0.95 cm<sup>2</sup> at ~70% confluency, using Lipofectamine 2000 (Invitrogen). Fifteen hours after transfection, the growth media was removed, and the cells were washed three times with DPBS. The cells were



_					
B)		HC3	HC4	PB3	PB4
	E20G/W37T	48.4 ± 0.4	31.1 ± 0.6	32.1 ± 0.9	6.5 ± 0.5
	E20A/W37T	25.2 ± 0.3	10.3 ± 0.9	19.0 ± 1.7	2.9 ± 0.03
	E20A/W37V	26.7 ± 1.4	1.1 ± 0.1	17.8 ± 0.3	0.4 ± 0.05
	E20S/W37I	36.8 ± 0.2	18.6 ± 0.2	7.9 ± 0.1	5.4 ± 0.02
	E20G/W37I	28.6 ± 0.2	3.6 ± 0.1	2.1 ± 0.02	3.8 ± 0.1
	W37V	37.4 ± 0.6	47.8 ± 0.5	N.D.	N.D.




Figure 2. Screening of LpIA mutants for Pacific Blue ligation activity. (A) Relative product conversions measured for 19 LplA single and double mutants with two hydroxycoumarin (HC) probes and two Pacific Blue (PB) probes. HC3 and PB3 have n = 3 linkers, and HC4 and PB4 have n = 4 linkers. To generate these grids, ligation reactions were performed under both forcing conditions (12 h, 500  $\mu$ M probe) and milder conditions (2 h, 50  $\mu$ M probe) and analyzed by ultraperformance liquid chromatography, as described in the Experimental Procedures. Sample traces are shown in Figure S2. The activity grid was generated with the following tiers: no activity, <25% conversion in a 12 h reaction, 25-50% conversion in a 12 h reaction, <25% conversion in 2 h reaction, 25-50% conversion in 2 h reaction, >50% conversion in 2 h reaction. (B) Quantitative product yields for the top five PB ligases in (A), after 45 min reaction with 500  $\mu M$  of each probe. N.D. indicates not detected. The best LplA mutants for PB3, HC3, and HC4 are highlighted. Errors are reported as standard errors of the mean. (C) HPLC trace showing formation of LAP-PB3 conjugate, catalyzed by our best PB ligase, E20G/W37TLplA. The identity of the LAP-PB3 peak was confirmed by mass spectrometry, shown in Figure S3. Traces below show negative control reactions with ATP omitted (red) or E20G/W37TLplA replaced by wild-type LplA (black).

labeled by applying 100  $\mu$ M Pacific Blue or hydroxycoumarin probe, 2  $\mu$ M ligase, 1 mM ATP, and 5 mM Mg(OAc)<sub>2</sub> in DPBS at room temperature for 40 min. Cells were then washed three times with DPBS and either imaged immediately or incubated at 37 °C for an additional 30 min to allow receptor internalization prior to imaging.

Intracellular Protein Labeling. HEK cells were transfected at ~70% confluency with 200 ng of LAP-YFP-NLS-pcDNA3 and 50 ng of FLAG- $^{\rm E20G/W37T}$ LplA-pcDNA3 per 0.95 cm² using Lipofectamine 2000 (Invitrogen). Fifteen hours after transfection, the growth media was removed, and the cells were washed three times with serum-free MEM. The cells were labeled by applying 20  $\mu$ M PB3-AM2 in serum-free MEM at 37 °C for 20 min. The cells were then washed three times with fresh MEM. Excess probe was removed by changing the media several times over 40 min.

To visualize LplA expression levels, cells were fixed using 3.7% formaldehyde in PBS pH 7.4 for 10 min, followed by methanol at  $-20~^\circ\mathrm{C}$  for 5 min. Fixed cells were washed with DPBS and then blocked overnight with blocking buffer (3% BSA in DPBS with 0.1% Tween-20). Anti-FLAG M2 antibody (Sigma) was added at a 1:300 dilution in blocking buffer for 1 h at room temperature. Cells were then washed three times with DPBS before treatment with a 1:300 dilution of goat antimouse antibody conjugated to Alexa Fluor 568 (Invitrogen) in blocking buffer for 1 h at room temperature. Cells were washed three times with DPBS prior to imaging.

For labeling of vimentin-LAP (Figure 4B), HeLa cells were transfected with 250 ng of vimentin-LAP-Clontech, 50 ng of FLAG-E20G/W37TLplA-pcDNA3, and 100 ng of H2B-YFP transfection marker per 0.95 cm² using Lipofectamine 2000. Labeling was performed as above, with an extended 60 min washout period to remove excess probe. Cells were then imaged live in DPBS.

We note that, compared to intracellular labeling with hydroxycoumarin, labeling with PB3 generally requires longer washout times, up to 60 min in some cases. Shorter wash times result in higher PB background in all cells.

## RESULTS

Screening for a Pacific Blue Ligase. On the basis of the LplA crystal structure (Figure 1B),8 we decided to focus our engineering efforts on the W37 and E20 positions. We started with a preliminary screen of 19 W37 point mutants and 14 E20 point mutants, against four probe structures (Figure S1). These four structures, shown in Figure 2A, are two Pacific Blue probes with shorter (n = 3) and longer (n = 4) linkers (PB3 and PB4) and two analogous 7-hydroxycoumarin probes (HC3 and HC4). Some Pacific Blue (PB) ligation product was detected after a 12 h reaction with W37T, V, I, and A LplA mutants (Figure S1), so we decided to introduce these mutations into our next screen. Note that the activity of the best point mutant,  $^{
m W37T}$ LplA, which gave  ${\sim}50\%$  conversion to PB ligation product after 12 h, is too slow for practical utility. For E20, none of the tested point mutants gave product with any of the four probes after 12 h. Nevertheless, in our next screen, we included E20 mutations to the smaller, neutral side chains Gly, Ala, and Ser.

Our next library consisted of 7 single mutants (four at W37 and three at E20) and their 12 crossed double mutants, shown in Figure 2A. Screening was performed using 500  $\mu$ M probe in an overnight reaction. Any ligase/probe combination with high activity under these conditions was reassayed using 50  $\mu$ M




Figure 3. Cell surface labeling with Pacific Blue ligase and imaging of internalized protein pools. HEK cells expressing LAP4.2-LDL receptor were labeled at the cell surface with either PB ligase and PB3, or HC ligase and HC4, for 40 min at room temperature. Cells were then imaged immediately (left side; 0 min internalization) or incubated for an additional 30 min at 37 °C to allow internalization of labeled LAP4.2-LDL receptor before imaging (right side). Pacific Blue and hydroxycoumarin channels are shown. Nuclear YFP was a cotransfection marker. All scale bars: 10 μm.




Figure 4. Intracellular protein labeling with Pacific Blue ligase. (A) HEK cells expressing LAP-YFP-NLS (NLS is a nuclear localization signal) and PB ligase ( $^{\rm E20G/W37T}$ LplA) were treated with PB3-AM $_2$  for 20 min, washed for 40 min, fixed with formaldehyde, and stained with anti-FLAG antibody to detect FLAG-tagged LplA. Images show PB labeling of transfected YFP-positive and FLAG-positive cells. The second row is a negative control with PB ligase replaced by wild-type LplA. The third row is a negative control with LAP-YFP-NLS replaced by a point mutant with a K  $\rightarrow$  A mutation in LAP. (B) HeLa cells expressing vimentin-LAP and PB ligase ( $^{\rm E20G/W37T}$ LplA) were labeled with PB3-AM $_2$  for 20 min, washed for 60 min, and then imaged live. Scale bars: 10  $\mu \rm m$ .

probe in a 2 h reaction. As before, the E20 single mutants had no detectable activity (Figure 2A). The W37 single mutants were minimally active with both PB probes, although high activity was seen with HC3 and HC4. The best single mutant/probe pair was W37VLplA with HC4.

The LplA double mutants, however, had interesting patterns of activity with PB. Although none of the mutants ligated PB4 efficiently, PB3 was ligated well by five double mutants (Figure 2A; re-evaluated quantitatively in Figure 2B). The best two have the W37T mutation, suggesting that not only size reduction but also polarity increase at this position is beneficial

for PB recognition. We noticed that the W37A mutation performed poorly in the context of all double mutants for all four probes, perhaps because it destabilizes the binding pocket. The best E20 mutation to pair with W37T was Gly, perhaps because it generates the most space and conformational freedom. Together, our observations suggest that W37 and E20 mutations work synergistically to allow PB uptake: W37 mutations enlarge the binding pocket, while E20 mutations remove repulsive electrostatic interactions (Figure 1C).

We proceeded to fully characterize our best PB ligase to emerge from this screen,  $^{\rm E20G/W37T}$ LplA. First, HPLC analysis of the ligation reaction was repeated (Figure 2C), alongside negative controls omitting ATP or replacing PB ligase with wild-type LplA. Second, the kinetic constants for PB3 ligation to LAP were measured by HPLC (Figure S4). Both  $k_{\rm cat}$  (0.014  $\pm$  0.001 s $^{-1}$ ) and  $K_{\rm M}$  (17.5  $\pm$  4.3  $\mu$ M) values are comparable to those previously determined for HC4 ligation catalyzed by  $^{\rm W37V}$ LplA ( $k_{\rm cat}$  0.019  $\pm$  0.004 s $^{-1}$  and  $K_{\rm M}$  56  $\pm$  20  $\mu$ M). Finally, we tested the sequence specificity of PB3 ligation by labeling a LAP fusion protein within mammalian cell lysate. Figure S5 shows that only LAP is labeled by PB ligase and not any endogenous mammalian proteins.

Cell Surface Labeling with Pacific Blue Ligase. To test our PB ligase on living cells, we first performed labeling of a cell surface protein. The neuronal adhesion protein neurexin- $1\beta$  with LAP4.2 (a variant of LAP<sup>5</sup> whose sequence is given in the Experimental Procedures) fused to its extracellular N-terminus was expressed in human embryonic kidney (HEK) cells. Labeling was performed by adding purified PB ligase, PB3 probe, and ATP to the cellular media for 30 min. Figure S6 shows a ring of PB fluorescence around cells expressing LAP4.2-neurexin, as indicated by the presence of the cotransfection marker, whereas untransfected neighboring cells are not labeled. Negative controls performed with wild-type LplA, ATP omitted, or an alanine mutation in LAP resulted in no visible labeling (Figure S6).

A potential advantage of PB ligase over HC ligase is for visualization of proteins in acidic organelles, where HC fluorescence is low due to its  $pK_a$  of 7.5. To test this experimentally, we used PB ligase or HC ligase to label LAP4.2-LDL receptor (low-density lipoprotein receptor) on the surface of HEK cells. After labeling, cells were incubated for 30 min at 37 °C to allow internalization of fluorescently tagged receptors. Figure 3 shows that PB-tagged LAP4.2-LDL receptor is clearly

visible within internalized puncta, whereas HC-tagged LAP4.2-LDL receptor is not. Separate experiments showed that many of the PB-labeled internal puncta overlap with FM4-64, an endosomal marker (data not shown).

Intracellular Protein Labeling with Pacific Blue Ligase. We tested PB ligase for labeling of intracellular proteins in living mammalian cells. To deliver PB3 across the cell membrane, we first protected the carboxylic acid and 7hydroxyl groups of PB3 with acetoxymethyl (AM) groups to give PB3-AM<sub>2</sub> (structure shown in Supporting Information). Endogenous intracellular esterases remove the AM groups to give PB3 inside the cell. 12 HEK cells were cotransfected with plasmids for PB ligase and LAP-YFP-NLS (NLS is a nuclear localization signal; YFP is yellow fluorescent protein). To perform labeling, PB3-AM2 was incubated with cells for 20 min, and then the media was replaced 3 times over 40 min to allow cells to pump out excess, unconjugated probe. The cells were then fixed, and anti-FLAG immunostaining was performed to visualize enzyme expression. As expected for specific labeling, PB fluorescence overlaps well with the YFP fluorescence of LAP-YFP-NLS (Figure 4). PB is not seen in neighboring untransfected cells. PB labeling is also absent when wild-type LplA is used in place of PB ligase, or the LAP-YFP-NLS contains a Lys  $\rightarrow$  Ala mutation in the LAP sequence. To illustrate generality, we also performed PB labeling in live cells of vimentin-LAP, an intermediate filament protein (Figure 4B).

## DISCUSSION

In this study, we identified an LplA double mutant capable of recognizing and ligating a charged probe, Pacific Blue. Unlike previous studies where simple enlargement of the binding pocket via a point mutation at W37 was sufficient to allow recognition of large hydrophobic probes, the synergistic effect of mutating both the E20 and W37 positions was required for recognition of Pacific Blue. Guided by the LplA crystal structure, we were able to create a small and focused library of single and double LpIA mutants to screen for the desired PB ligation activity. No single mutation had significant activity, but the augmentation of the most active W37 single mutants by E20 mutations resulted in a kinetically efficient PB ligase. We anticipate that these insights into the substrate binding pocket of LplA will prove useful in future engineering efforts. The engineered PB ligase has  $k_{\text{cat}}$  and  $K_{\text{M}}$  values similar to those of our previously reported 7-hydroxycoumarin ligase.<sup>2</sup> PB ligase also retained sequence specificity for LAP over all endogenous mammalian proteins and could therefore be used for specific protein labeling inside and on the surface of living mammalian cells.

With this report, PRIME labeling can now be performed with any of three coumarin probes: Pacific Blue, 7-hydroxycoumarin,  $^2$  or 7-aminocoumarin (AC). The decision of which coumarin to use is dependent on the specific application. HC is the brightest of the three probes, followed by PB and then AC due to its decreased extinction coefficient. However, as demonstrated here, PB and AC have the added benefit of pH insensitivity, whereas the p $K_a$  of HC makes it unsuitable for imaging in acidic organelles such as endosomes.

### ASSOCIATED CONTENT

# Supporting Information

Figures S1-S6 showing screening data, kinetic measurements, labeling in cell lysate, and cell surface labeling with negative controls; synthetic methods, modeling information, and

additional experimental details. This material is available free of charge via the Internet at http://pubs.acs.org.

## AUTHOR INFORMATION

## **Corresponding Author**

\*Phone: (617) 452-2021. Fax: (617) 253-7929. E-mail: ating@mit.edu.

## **Funding**

This work was supported by the National Institutes of Health (R01 GM072670), the Dreyfus Foundation, the American Chemical Society, and MIT.

#### ACKNOWLEDGMENTS

The authors thank Hemanta Baruah, Chayasith Uttamapinant, Katharine White, and Daniel Liu for plasmids and helpful advice. Michael Lewandowski of the Broad Institute of MIT and Harvard assisted with liquid chromatography-based screens.

#### REFERENCES

- (1) Cronan, J. E., Zhao, X., and Jiang, Y. F. (2005) Function, attachment and synthesis of lipoic acid in Escherichia coli. *Adv. Microb. Physiol.* 50, 103–146.
- (2) Uttamapinant, C., White, K. A., Baruah, H., Thompson, S., Fernandez-Suarez, M., Puthenveetil, S., and Ting, A. Y. (2010) A fluorophore ligase for site-specific protein labeling inside living cells. *Proc. Natl. Acad. Sci. U.S.A.* 107, 10914–10919.
- (3) Baruah, H., Puthenveetil, S., Choi, Y. A., Shah, S., and Ting, A. Y. (2008) An engineered aryl azide ligase for site-specific mapping of protein-protein interactions through photo-cross-linking. *Angew. Chem., Int. Ed.* 47, 7018–7021.
- (4) Fernandez-Suarez, M., Baruah, H., Martinez-Hernandez, L., Xie, K. T., Baskin, J. M., Bertozzi, C. R., and Ting, A. Y. (2007) Redirecting lipoic acid ligase for cell surface protein labeling with small-molecule probes. *Nature Biotechnol.* 25, 1483–1487.
- (5) Puthenveetil, S., Liu, D. S., White, K. A., Thompson, S., and Ting, A. Y. (2009) Yeast Display Evolution of a Kinetically Efficient 13-Amino Acid Substrate for Lipoic Acid Ligase. *J. Am. Chem. Soc.* 131, 16430–16438.
- (6) Hinner, M. J., and Johnsson, K. (2010) How to obtain labeled proteins and what to do with them. *Curr. Opin. Biotechnol.* 21, 766–776
- (7) Sun, W. C., Gee, K. R., and Haugland, R. P. (1998) Synthesis of novel fluorinated coumarins: Excellent UV-light excitable fluorescent dyes. *Bioorg. Med. Chem. Lett.* 8, 3107–3110.
- (8) Fujiwara, K., Maita, N., Hosaka, H., Okamura-Ikeda, K., Nakagawa, A., and Taniguchi, H. (2010) Global Conformational Change Associated with the Two-step Reaction Catalyzed by Escherichia coli Lipoate-Protein Ligase A. J. Biol. Chem. 285, 9971–
- (9) Jin, X., Uttamapinant, C., and Ting, A. Y. (2011) Synthesis of 7-Aminocoumarin by Buchwald-Hartwig Cross Coupling for Specific Protein Labeling in Living Cells. *ChemBioChem* 12, 65–70.
- (10) Zou, P., and Ting, A. Y. (2011) Imaging LDL Receptor Oligonnerization during Endocytosis Using a Co-internalization Assay. ACS Chem. Biol. 6, 308–313.
- (11) Howarth, M., Liu, W. H., Puthenveetil, S., Zheng, Y., Marshall, L. F., Schmidt, M. M., Wittrup, K. D., Bawendi, M. G., and Ting, A. Y. (2008) Monovalent, reduced-size quantum dots for imaging receptors on living cells. *Nature Methods* 5, 397–399.
- (12) Tsien, R. Y. (1989) Fluorescent-Probes of Cell Signaling. *Annu. Rev. Neurosci.* 12, 227–253.
- (13) Avogadro: an open-source molecular builder and visualization tool. Version 1.0.1. 2010. Ref Type: Computer Program.